BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BYSI
Previous Symbol
CUSIPN/A
Phone1-646-305-6387
Debt
Debt-to-Equity RatioN/A
Current Ratio4.36
Quick Ratio4.36
Price-To-Earnings
Trailing P/E Ratio-5.26
Forward P/E Ratio-10.29
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book18.82
Profitability
EPS (Most Recent Fiscal Year)($4.40)
Net Income$-91,760,000.00
Net MarginsN/A
Return on Equity-251.49%
Return on Assets-201.71%
Miscellaneous
Employees38
Outstanding Shares22,440,000
Market Cap$477.88 million
OptionableNot Optionable
Beyondspring (NASDAQ:BYSI) Frequently Asked Questions
What is Beyondspring's stock symbol?
Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."
How were Beyondspring's earnings last quarter?
Beyondspring Inc (NASDAQ:BYSI) issued its quarterly earnings data on Tuesday, October, 23rd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.08. View Beyondspring's Earnings History.
When is Beyondspring's next earnings date?
What price target have analysts set for BYSI?
3 brokerages have issued 1-year price objectives for Beyondspring's stock. Their forecasts range from $35.00 to $60.00. On average, they anticipate Beyondspring's share price to reach $50.3333 in the next twelve months. This suggests a possible upside of 117.4% from the stock's current price. View Analyst Price Targets for Beyondspring.
What is the consensus analysts' recommendation for Beyondspring?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beyondspring.
What are Wall Street analysts saying about Beyondspring stock?
Here are some recent quotes from research analysts about Beyondspring stock:
- 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (10/26/2018)
- 2. Maxim Group analysts commented, "BeyondSpring reported 3Q18 (on 10/23) with expenses of $12.4M. The company ended the period with a cash balance of $22.4M. The company has runway into early 2019 though we expect BYSI needs to raise capital. Combined with the recent pullback in valuation, driven in part by macro factors such as contracting multiples in the healthcare space, we lower our price target to $35, from $48 – still plenty of upside." (10/25/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating with a $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (6/22/2018)
Has Beyondspring been receiving favorable news coverage?
News stories about BYSI stock have trended neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Beyondspring earned a news impact score of 0.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Beyondspring's key competitors?
Some companies that are related to Beyondspring include Global Blood Therapeutics (GBT), Ironwood Pharmaceuticals (IRWD), AnaptysBio (ANAB), Reata Pharmaceuticals (RETA), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), Zogenix (ZGNX), Innoviva (INVA), Cambrex (CBM), Enanta Pharmaceuticals (ENTA), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), The Medicines (MDCO), Theravance Biopharma (TBPH) and Spectrum Pharmaceuticals (SPPI).
Who are Beyondspring's key executives?
Beyondspring's management team includes the folowing people:
- Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 47)
- Mr. Dongheng Liu, Chief Financial Officer (Age 36)
- Mr. Richard J. Daly, Chief Operating Officer (Age 57)
- Ms. Amy Yang, Controller
- Dr. Ramon W. Mohanlal, Chief Medical Officer of BeyondSpring U.S. (Age 60)
When did Beyondspring IPO?
(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.
Who are Beyondspring's major shareholders?
Beyondspring's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tanaka Capital Management Inc. (0.22%).
Which major investors are buying Beyondspring stock?
BYSI stock was bought by a variety of institutional investors in the last quarter, including Tanaka Capital Management Inc..
How do I buy shares of Beyondspring?
Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Beyondspring's stock price today?
One share of BYSI stock can currently be purchased for approximately $23.1501.
How big of a company is Beyondspring?
Beyondspring has a market capitalization of $477.88 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. Beyondspring employs 38 workers across the globe.
What is Beyondspring's official website?
How can I contact Beyondspring?
Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]
MarketBeat Community Rating for Beyondspring (NASDAQ BYSI)
MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
